A novel experimental drug for early Parkinson's disease (PD) yielded similar results as commercially available pramipexole extended-release (ER) but with significantly less daytime sleepiness, a new study shows.
The findings are the latest from a phase 3 trial of P2B001, an experimental drug that combines low-dose, ER formulations of pramipexole and rasagiline. Both drugs are already available at higher dosages. Extended-release rasagiline is not commercially available.
Is propofol safe for a colonoscopy with Parkinson’s?
Amantadin extended release 
Significant cost increase for ER Sinemet?
LDN drug with no side effects
Colonoscopy while on Parkinson's Meds
